PHI with Basal cell carcinoma
How does this condition affect your private health insurance?
Basaliom, or Basal Cell Carcinoma (BCC), is the most prevalent type of skin cancer, originating from the basal cells of the epidermis. Primarily caused by chronic ultraviolet (UV) radiation exposure from sun or tanning beds, it commonly appears on sun-exposed areas like the face and neck. BCC typically presents as a pearly nodule, a flat, flesh-colored lesion, or a persistent sore. While it rarely metastasizes, it can be locally destructive, invading surrounding tissues and bone if left untreated for extended periods. Early detection and timely treatment, usually surgical, are highly effective in achieving a cure, minimizing disfigurement, and preventing recurrence at the treated site.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 25%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Months to years (development); days to weeks (treatment and initial recovery)
Duration of Illness (Lifetime)
Potentially recurrent; chronic risk over a lifetime for new lesions
Cost of Treatment (Initial)
Varies widely, typically $500 - $5,000 USD, depending on size, location, and treatment method (e.g., excision, Mohs surgery)
Cost of Treatment (Lifetime)
Potentially $1,000 - $20,000+ USD, considering follow-ups and treatment of potential new lesions
Mortality Rate
Less than 0.1%, primarily in very rare cases of aggressive, neglected, or deeply invasive tumors
Risk of Secondary Damages
High (20-50%) for local tissue damage, scarring, or disfigurement, especially if large or located on cosmetically sensitive areas; moderate for psychological distress
Probability of Full Recovery
Very high, >95% with proper and timely treatment, without recurrence at the treated site
Underlying Disease Risk
Low, but increased risk of other skin cancers (e.g., squamous cell carcinoma, melanoma) due to shared risk factors like UV exposure. Higher in rare genetic predisposition syndromes.